Evaluating the Clinical Efficacy, Utility, and Role of the 40-Gene Expression Profiling Test in Assessing Prognosis of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel
Journal of Drugs in Dermatology · 01.11.2026 · 25 (11) · 1051-1057
DOI: 10.36849/jdd.9901 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Drugs in Dermatology, online erschienen am 01.10.2026. Verfasst von Joshua Burshtein und 13 weiteren Autor:innen. Hauptthemen laut MEDLINE: Skin Neoplasms, Cutaneous Squamous Cell Carcinoma, Gene Expression Profiling.
Abstract (Originalsprache)
BACKGROUND: The 40-gene expression profiling (40-GEP) test has been validated to identify patients at highest risk for nodal or distant metastasis, as well as those most likely to benefit from adjuvant radiation therapy (ART). The purpose of this expert consensus panel was to review the published literature on the clinical efficacy, utility, and role of the 40-GEP test in providing prognostic information for high-risk cSCC. METHODS: A comprehensive literature search was completed using a combination of keywords "40-gene expression profiling," "cutaneous squamous cell carcinoma," "prognosis," "clinical efficacy," and "clinical utility". A panel of 8 dermatologists with significant expertise in management of cSCC gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement, and a strength of recommendation was assigned. RESULTS: The literature search produced 55 articles. Screening resulted in 18 articles that met criteria. The panel unanimously "voted to adopt 8 consensus statements and recommendations: 5 with strength "A", 2 with strength "B", and 1 with strength "C. CONCLUSION: The 40-GEP test augments staging accuracy by improving metastatic and local recurrence risk stratification beyond traditional staging systems. It also has clinical utility in informing decisions regarding adjuvant radiation therapy and guiding broader management strategies. .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Zitieren
APA
Burshtein, J., Rosenberg, A., Arron, S. T., Bartley, B., Cotter, D., Desai, S. R., DeBusk, L., Farberg, A., Nguyen, H. P., Schlesinger, T., Shah, M., Zakria, D., Zeitouni, N., & Rigel, D. (2026). Evaluating the Clinical Efficacy, Utility, and Role of the 40-Gene Expression Profiling Test in Assessing Prognosis of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology, 25(11), 1051-1057. https://doi.org/10.36849/jdd.9901
Vancouver
Burshtein J, Rosenberg A, Arron ST, Bartley B, Cotter D, Desai SR, et al. Evaluating the Clinical Efficacy, Utility, and Role of the 40-Gene Expression Profiling Test in Assessing Prognosis of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel. Journal of Drugs in Dermatology. 2026;25(11):1051-1057. doi:10.36849/jdd.9901
BibTeX
@article{Burshtein2026,
author = {Burshtein, Joshua and Rosenberg, Angela and Arron, Sarah T and Bartley, Brooke and Cotter, David and Desai, Seemal R and DeBusk, Lauren and Farberg, Aaron and Nguyen, Harrison P and Schlesinger, Todd and Shah, Milaan and Zakria, Danny and Zeitouni, Nathalie and Rigel, Darrell},
title = {Evaluating the Clinical Efficacy, Utility, and Role of the 40-Gene Expression Profiling Test in Assessing Prognosis of Cutaneous Squamous Cell Carcinoma: An Expert Consensus Panel},
journal = {Journal of Drugs in Dermatology},
year = {2026},
volume = {25},
number = {11},
pages = {1051--1057},
doi = {10.36849/jdd.9901}
}
EUVIMED